🔗 Visit the ClinicalTrials.gov page for NCT02088112
Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. | J Hematol Oncol | 2016 | 1.12 |
2 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 1.06 |
3 | Cancer immunotherapy in clinical practice -- the past, present, and future. | Chin J Cancer | 2014 | 0.98 |
4 | Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. | BMC Med | 2016 | 0.83 |
5 | FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. | Cell Death Discov | 2015 | 0.80 |
6 | Challenges and future perspectives of T cell immunotherapy in cancer. | Immunol Lett | 2015 | 0.78 |
7 | A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. | Cancer Discov | 2014 | 0.77 |
8 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. | Onco Targets Ther | 2016 | 0.75 |